Azano Pharmaceuticals Inc Profile last edited on: 6/17/21
CAGE: 5SYA7
UEI:
Business Identifier: C-reactive protein derivatives to treat Systemic Lupus Erythematosus (SLE) & other autoimmune diseases Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
5901 Indian School Road Northeast
Albuquerque, NM 87110
Albuquerque, NM 87110
(505) 272-7963 |
jmac@azanopharma.com |
www.azanopharma.com |
Location: Single
Congr. District: 01
County: Bernalillo
Congr. District: 01
County: Bernalillo
Public Profile
Anchored in work undertaken and IP issued to University of New Mexico Health Center and the Alburqueque Department of Veteran's Affairs Azano Pharmaceuticals had been organized around harnessing the power of small molecules and proteins to develop innovative therapies. In addition to the commercialization of the GPER ligands, Azano had been actively pursuing the development of a C-reactive protein (CRP) derivative to treat Systemic Lupus Erythematosus (SLE) and other autoimmune diseases. As on mid-teens, wenbiste is non functional and principals of the firm appear to have relocated elsewhere suggesting the firm has dicontinued perioations.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2010 | 1 | NIH | $146,716 | |
Project Title: Modified C-Reactive Protein For Novel Treatment Of Lupus Nephritis. |
Key People / Management
Waneta Tuttle -- Chief Executive Officer
John A MacDonald -- Chief Science Officer
Michael Perrine -- Business Development Executive
John A MacDonald -- Chief Science Officer
Michael Perrine -- Business Development Executive